Clinical Trials · NCT01480986
IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Peking University
- Enrollment
- 40
- Start date
- Sep 2011
- Locations
- 1 site, China
- Primary endpoint
- Progression Free Survival for Irinotecan plus cisplatin and octreotide